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The clinical significance of antiphospholipid antibodies (aPL) in the context of infections
has attracted attention since their first discovery in patients with syphilis. In fact, the
recognition of aPL in patients with infections has been described in parallel to the
understating of the syndrome. Since the first description of aPL-positive tests in three
patients with COVID-19 diagnosed in January 2020 in Wuhan, China, a large number of
studies took part in the ongoing debate on SARS-2-Cov 2 induced coagulopathy, and
many following reports speculated a potential role for aPL. In order to get further insights
on the effective role of detectable aPL in the pro-thrombotic status observed in COVID-19
patients, we performed an observational age-sex controlled study to compare the aPL
profile of hospitalized patients with COVID with those observed in a) patients with
thrombotic APS and b) patients with cultural/serologically-proved infections. Our data
showed positive aPL testing in about half of the patients (53%) with COVID-19 and
patients with other viral/bacterial infections (49%). However, aPL profile was different
when comparing patients with overt APS and patients with aPL detected in the contest of
infections. Caution is therefore required in the interpretation and generalization of the role
of aPL s in the management of patients with COVID-19. Before introducing aPL testing as
a part of the routine testing in patients with COVID-19, larger well-designed clinical studies
are required. While the pro-thrombotic status in patients with COVID-19 is now
unquestionable, different mechanisms other than aPL should be further investigated.
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The antiphospholipid syndrome (APS) is a systemic autoimmune condition characterized by the
persistent elevation of antiphospholipid antibodies (aPL), such as anticardiolipin antibodies (aCL),
lupus anticoagulant (LA), and anti-beta2 Glycoprotein 1 (ab2GPI), in patients with
thromboembolic events and/or pregnancy-related morbidity (1) (Box 1). The clinical significanceorg June 2021 | Volume 12 | Article 6875341
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their first discovery in patients with syphilis (2). In fact, the
recognition of aPL in patients with infections has been described
in parallel to the understating of the syndrome (3). Since the
global outbreak of the COVID-19 pandemic, a potential
relationship between the presence of aPL and the new has been
largely debated.
First, Zhang and co-workers (4) reported a 69-year-old man
with COVID-19 diagnosed in January 2020 in Wuhan, China,
along with two other critically ill patients with COVID-19 who
were also seen in the same intensive care unit. aPL were detected
in all three patients. Since then, a large number of studies took
part in the ongoing debate on SARS-2-Cov 2–induced
coagulopathy, and many following reports speculated a
potential role for aPL.
Recently, Zou et al. (5), when testing 172 patients hospitalized
with COVID-19 for an extended panel of aPL, found that aPL
were present in up to 52% of serum samples using the
manufacturer’s threshold and in 30% using a more stringent
cut-off (≥40 ELISA-specific units). In detail, among the various
aPL antibodies tested, anti-phosphatidylserine/prothrombin
(aPS/PT) IgG had the highest prevalence (24%), followed by
aCL IgM (23%) and aPS/PT IgM (18%). Forty-one patients
(24%) were positive for more than one type of aPL antibody,
and 13 (8%) were positive for more than two types of aPL
antibody. Fifty-two patients (30%) had at least one moderate- to
high-titer aPL antibody. Interestingly, they reported that IgG
fractions isolated from patients with COVID-19 and high serum
titers for aPS/PT IgG increased thrombus extension in a murine
model. While the pro-thrombotic profile of patients with
COVID-19 is unquestionable, the specific role of aPL in this
setting still requires further considerations.
Do the detectable aPL actively participate in the pro-
thrombotic status observed in COVID-19 patients or they
represent an epiphenomenon in the context of the infection, as
previously described in other settings?
In order to get further insights on the effective role of
detectable aPL in the pro-thrombotic status observed in
COVID-19 patients, we performed an observational age-sex
controlled study to compare the aPL profile of hospitalized
patients with COVID with those observed in a) patients with
thrombotic APS and b) patients with cultural/serologically-
proved infections.Frontiers in Immunology | www.frontiersin.org 2METHODS
We included 261 patients (divided in three age and sex-matched
controls groups of 87 patients):
1) Consecutive PCR-confirmed COVID-19–infected patients
admitted at the AO Ordine Mauriziano Hospital, Torino, Italy
2) Age- and sex-matched controls with viral and bacterial
infections* and no previous history of thrombotic events
attending the S. Giovanni Bosco Hospital, Torino, Italy
3) Age and sex-matched patients with APS fulfilling Sidney’s criteria
(1) admitted at the S. Giovanni Bosco Hospital, Torino, Italy
The aetiology of infections was: 24 cases of Treponema pallidum,
18 cases of cytomegalovirus, 10 cases of Influenza H3N2, 10 of E.
coli, 8 of Streptococcus pneumoniae, 7 of parvovirus B19, 7 of
Epstein-Barr virus, and 2 of Pseudomonas aeruginosa (Table 1).
The IgG/IgM isotype for aCL, ab2GPI and aPS/PT were
detected by commercial ELISA (Inova Diagnostics, Inc., San
Diego, CA, US).
LA was tested as per the current criteria from the
International Society of Thrombosis and Haemostasis (ISTH)
Subcommittee on LA-Phospholipid-dependent antibodies (6).
The significance of baseline differences was determined by the
chi-squared test, Fisher’s exact test or the unpaired t-test, as
appropriate. A two-sided P-value <0.05 was statistically
significant. All statistical analyses were performed using SPSS
version 26.0 (IBM, Armonk, NY, USA).RESULTS
A total of 261 patients were enrolled in this study, 87 patients for
each group: patients with COVID-19 infection, matched-
controls with infections other than COVID-19 and matched-
APS patients. As per classification criteria, all patients with APS
were positive for aPL, while a high rate of patients positive for at
least one aPL (IgG/IgM) was observed similarly in patients with
COVID-19 infection (46; 52.9%) and controls suffering with
other infections (43; 49.4%).
PCR-confirmed COVID-19–infected patients were tested for
aPL at the time of the admission in the Hospital, 84 patients
(96.7%) were treated with low molecular weight heparins. Only
one patient developed a deep vein thrombosis during the
admission. Table 1 resumes the rate of positive antiphospholipid
antibodies’ testing and relative differences between groups.
When focusing on criteria aPL, as expected, APS patients had
significantly higher rates of positive testing for LA when compared
with the other groups [87.4% vs. 29.9% (COVID-19) and vs. 47.1%
(infections)] and for IgG isotype of aß2GPI [47.1% vs. 13.8%
(COVID-19) and vs. 12.6% (infections)] and aCL [48.3% vs. 12.6%
(COVID-19) and vs. 12.6% (infections)]. Also, when looking at
multiple criteria aPL positive test (considering IgG and/or IgM
isotypes), the APS group had significantly higher rates of double
aPL positive testing [43.7% vs. 8% (COVID-19) and vs. 18.4%BOX 1 | Classification criteria of the Antiphospholipid Syndrome.
Clinical criteria
• Thrombosis affecting the arteries, veins, or small blood vessels and/or
• Adverse outcomes during pregnancies (three or more spontaneous
abortions before 10th week of pregnancy, unexplained fetal deaths at
or beyond 10th week of pregnancy, or premature births before 34th
week of pregnancy due to severe preeclampsia or eclampsia)Laboratory criteria (antiphospholipid antibody tests, to be confirmed at 12 weeks)
• Positive lupus anticoagulant test and/or
• Positive anticardiolipin antibody (aCL) IgG and/or IgM and/or
• Positive anti-Beta-2-glycoprotein-I antibody (ab2GPI) IgG and/or IgMJune 2021 | Volume 12 | Article 687534
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19) and vs. 8% (infections)].
The trend was confirmed also when considering aPS/PT
testing, as non-criteria aPL. APS patients were the only group
with patients that tested positive for aPS/PT IgG (39.1%) and had
significantly higher rates of aPS/PT IgM testing [58.6% vs. 8%
(COVID-19) and vs. 25.3% (infections)]. Additionally, 34.5% of
APS patients tested positive for both all three criteria aPL and
aPS/PT IgG/M (tetra positive patients), when compared to only
three patients of the infections group and no patients in the
COVID-19 infection group.
The results of the analysis, for both criteria and non-criteria
aPL, were also confirmed when analyzing the titers of the aPL
tested (Table 1).
Figure 1 graphically illustrates the different rate of aPL
positive testing between groups.
No patients with aPL-positive test reported any thrombotic
events (both COVID-19 and infections group). In the COVID-19
group, we observed that no previously positive solid phase aPL test
was confirmed when re-testing 12 patients at more than 12 weeks
part. Of those, of the five LA-positive tests, only two were
confirmed, albeit with a marked reduction of LA potency.DISCUSSION
Our data showed positive aPL testing in about half of the patients
(53%) with COVID-19 and patients with other viral/bacterial
infections (49%). In detail, we found that a positive test for LA
can be detected in up to one out of three symptomatic
COVID-19 patients when tested according to the ISTH (6).
However, the so called triple aPL positivity (concomitant
presence of LA, aCL, and ab2GPI antibodies), the aPL profile
most strongly associated with a thrombotic event in patients withFrontiers in Immunology | www.frontiersin.org 3APS, has been observed in only two patients (2%). More
importantly, most of the aCL and ab2GPI antibodies positive
testing was detected at the low-medium titer. Interestingly, in our
cohort, no patient with infection (both in the COVID-19 or
infection groups) was found positive for aPS/PT IgG.
aPL positivity are known to be detectable during infections, to
include viral diseases, such as HIV and hepatitis C. The presence
of aPL in these contexts is often transient and almost always
non-specific (non-thrombosis-related). While syphilis is
notorious for the possible determination of aPL, when
considering our cohort, we did not observe a different rate of
aPL positive testing between patients with syphilis when
compared to other infections. However, it is likely that the
sample size limited the feasibility of any additional sub-analysis.
When comparing our data to Zuo et al. (5), some considerations
areworthnoting. So far, LA-positive testingwas themostly frequently
reported among patients with COVID tested for aPL. From this
perspective, as a limit to their analysis, they acknowledged that theLA
test was not performed given lack of access to fresh plasma samples.
When considering solid-phase aPL assays, methods that are in
principle insensitive to anticoagulation and other confounding
agents, the presence of aPL in patients with COVID-19 was
recently reported in a handful of case reports and small cohorts of
patients (7, 8). While encouraging, these data are limited and its
interpretation remains controversial, with some investigators
proposing an important role of aPL in COVID-19 patients (7, 8)
while others suggesting no association between aPL and thrombotic
events (9, 10). There is no information on the antigen specificity of
COVID-19 aPL in comparison with APS antibodies. Such
information and a larger study, possibly multicenter, may be
instrumental to clarify the real clinical value of these autoantibodies.
Our results support what Borghi et al. suggested (9). In fact,
when testing for aPL by both ELISA and chemiluminescence 122










(Group B vs. C)
Group C Patients
with APS (n = 87)
P value
(Group B vs. C)
Lupus Anticoagulant positive (n) 41 0.02 26 <0.0001 76 <0.0001
b2GPI IgM positive(n) 17 0.002 4 n.s. 9 0.046
b2GPI IgM titers (U/mL; mean ± SD) 25.8 ± 57.1 0.0003 2.7 ± 5.6 n.s. 9.9 ± 28.3 n.s.
b2GPI IgG positive(n) 11 n.s. 12 <0.0001 41 <0.0001
b2GPI IgG titers (U/mL; mean ± SD) 12 ± 14.6 n.s. 8 ± 8.9 <0.0001 57.9 ± 92.4 <0.0001
aCL IgM positive(n) 18 0.0004 4 <0.0001 28 0.0015
aCL IgM titers (U/mL; mean ± SD) 19.8 ± 33 n.s. 3.8 ± 5.3 n.s. 17.5 ± 36.8 n.s.
aCL IgG positive(n) 11 n.s. 11 0.002 42 0.002
aCL IgG titers (U/mL; mean ± SD) 14.7 ± 27.8 n.s. 10.1 ± 16.3 <0.0001 69.3 ± 108.3 <0.0001
aPS/PT IgM positive (n) 22 0.0005 7 <0.0001 51 <0.0001
aPS/PT IgM titers (U/mL; mean ± SD) 36.1 ± 48.9 <0.0001 10.6 ± 15.7 <0.0001 137 ± 133.5 <0.0001
aPS/PT IgG positive (n) 0 n.s. 0 <0.0001 34 <0.0001
aPS/PT IgG titers (U/mL; mean ± SD) 9.3 ± 6.2 <0.0001 3.7 ± 4.3 <0.0001 83.8 ± 101.9 <0.0001
Double Criteria aPL positive (IgG/IgM) (n) 16 0.043 7 <0.0001 38 <0.0001
Triple Criteria aPL positive (IgG/IgM) (n) 7 n.s. 2 <0.0001 35 <0.0001
Triple Criteria aPL (IgG/IgM) and aPS/PT
(IgG/IgM) positive (n)
3 n.s. 0 <0.0001 30 <0.0001June 2021 | Volume 12APS, antiphospholipid Syndrome; aPL, antiphospholipid antibodies; aPS/PT, anti-phosphatidylserine/prothrombin antibodies; ab2GPI, anti-b2-glycoprotein-I antibodies;
aCL, anticardiolipin antibodies; Ig, immunoglobulin; n.s., non significant.| Article 687534
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6.6 and 9.0% of patients. aCL IgG/IgM was detected in 5.7/6.6%
and aPS/PT IgG/IgM were detectable in 2.5% and 9.8%.
Critically, no association between thrombosis and aPL was
found. Reactivity against domain 1 and 4 to 5 of b2GPI was
limited to 3/58 (5.2%) tested sera for each domain and did not
correlate with aCL/anti-b2GPI nor with thrombosis.
Some limitations should be acknowledged. Patients enrolled
in the control infectious group were chart review-selected by
matching cases for sex and age group with 1 year difference
allowance. Taking this into account, it was out of the scope of this
paper to report on any estimations on specific infection rates or
epidemiological inference for this group and to provide evidence
on the potential impact of clinical disease on aPL development.
Similarly, it was out of the scope of this study to investigate
thrombosis rates in patients with COVID-19 infections.
In such a dramatic moment globally, researchers are called to
the urgent need for a better understanding of COVID-19–related
syndrome. On the other hand, before solid evidence is available,
caution is warranted to minimize the risk of unjustified requests
for tests to be performed in laboratories that are already
overloaded during the ongoing health emergency. Besides, with
the current level of evidence, the new detection of aPL in a
patient with COVID-19 should not guide the management of the
anti-thrombotic therapy that should be based on the available
international guidelines.
In conclusion, caution is therefore required in the
interpretation and generalization of the role of aPL such as
aPS/PT in the management of patients with COVID-19. Before
introducing aPL testing as a part of the routine testing in patients
with COVID-19, larger well-designed clinical studies are
required. While the pro-thrombotic status in patients withFrontiers in Immunology | www.frontiersin.org 4COVID-19 is now unquestionable, different mechanisms other
than aPL should be further investigated.DATA AVAILABILITY STATEMENT
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